Metabolic Reprogramming in Hepatocellular Carcinoma: Liver-Specific Immune Dysfunction, Immunotherapy Resistance, and Translational Biomarker Development.
Abstract
Hepatocellular carcinoma (HCC) arises in chronically injured, often fibrotic or cirrhotic liver, where metabolism, immunity, vascular and stromal organization, disease etiology, tumor state, and hepatic reserve are tightly interconnected. Although immune checkpoint inhibitor (ICI)-based therapies have expanded treatment options for advanced HCC, responses remain heterogeneous because of both primary and acquired resistance. Metabolic reprogramming may shape these outcomes by altering nutrient availability, metabolite accumulation, antigen presentation, immune-cell fitness, stromal organization, and spatial immune access. This review provides an evidence-weighted assessment of major immunometabolic mechanisms in HCC, focusing on the glycolysis-hypoxia-lactate and tryptophan-kynurenine/IDO1 axes, lipid and cholesterol metabolism, purinergic signaling, mitochondrial and redox regulation, and ferroptosis. We emphasize that these pathways are context dependent, with effects determined by cellular source, differentiation state, spatial organization, and tumor-intrinsic versus immune-cell metabolic adaptation. Molecular heterogeneity, etiology, and cirrhosis are considered together, with WNT-β-catenin/CTNNB1-associated states illustrating their intersection with immune organization and ICI response. Because translational maturity varies widely, we distinguish mechanistic evidence, biomarker association, predictive validation, and clinical utility. We propose a framework integrating HCC specificity, primary human validation, cellular and spatial localization, causal immune-functional evidence, treatment-linked and longitudinal assessment, biomarker feasibility, and liver-specific safety. The framework also considers intervention timing and the distinction between primary and acquired ICI resistance. It may guide progression from metabolic discovery to spatially resolved mechanism, biomarker development, pharmacodynamic validation, and clinical evaluation while accounting for cirrhosis-associated remodeling, hepatic reserve, and treatment-related toxicity.